- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00636064
A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery
2008년 10월 9일 업데이트: Pfizer
A Double-Blind Multicenter Study of the Safety and Efficacy of Parecoxib Sodium/Valdecoxib and Placebo/Valdecoxib Compared to Placebo for Treatment of Post-Surgical Pain in Patients Who Have Coronary Bypass Graft Via Median Sternotomy
The purpose of this study is to evaluate the efficacy and safety of parecoxib/valdecoxib therapy and placebo/valdecoxib therapy for the treatment of pain after coronary artery bypass surgery
연구 개요
연구 유형
중재적
등록 (실제)
1671
단계
- 3단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
-
Bloemfontein, 남아프리카, 9300
- Pfizer Investigational Site
-
Pretoria, 남아프리카, 0002
- Pfizer Investigational Site
-
Pretoria, 남아프리카, 0040
- Pfizer Investigational Site
-
-
Free State
-
Bloemfontein, Free State, 남아프리카
- Pfizer Investigational Site
-
-
Gauteng
-
Pretoria, Gauteng, 남아프리카
- Pfizer Investigational Site
-
Pretoria, Gauteng, 남아프리카, 0002
- Pfizer Investigational Site
-
Pretoria, Gauteng, 남아프리카, 0084
- Pfizer Investigational Site
-
-
Gauteng Province
-
Johannesburg, Gauteng Province, 남아프리카
- Pfizer Investigational Site
-
Pretoria, Gauteng Province, 남아프리카, 0140
- Pfizer Investigational Site
-
-
KwaZulu Natal
-
Durban, KwaZulu Natal, 남아프리카
- Pfizer Investigational Site
-
-
Pretoria
-
Les Marais, Pretoria, 남아프리카, 0084
- Pfizer Investigational Site
-
-
Western Cape
-
Parow, Western Cape, 남아프리카, 7500
- Pfizer Investigational Site
-
-
-
-
-
Breda, 네덜란드, 4836 AE
- Pfizer Investigational Site
-
Eindhoven, 네덜란드, 5623 EJ
- Pfizer Investigational Site
-
Zwolle, 네덜란드, 8011 JW
- Pfizer Investigational Site
-
-
-
-
-
Feiring, 노르웨이, 2093
- Pfizer Investigational Site
-
-
-
-
-
Kobenhavn, 덴마크, 2100
- Pfizer Investigational Site
-
Odense C, 덴마크, 5000
- Pfizer Investigational Site
-
-
-
-
-
Aachen, 독일, 52074
- Pfizer Investigational Site
-
Bonn, 독일, 53105
- Pfizer Investigational Site
-
Giessen, 독일, 35385
- Pfizer Investigational Site
-
Goettingen, 독일, 37075
- Pfizer Investigational Site
-
Hamburg, 독일, 20251
- Pfizer Investigational Site
-
Heidelberg, 독일, 69120
- Pfizer Investigational Site
-
Kassel, 독일, 34125
- Pfizer Investigational Site
-
Kiel, 독일, 24105
- Pfizer Investigational Site
-
Muenchen, 독일, 81377
- Pfizer Investigational Site
-
Muenster, 독일, 48149
- Pfizer Investigational Site
-
-
-
-
-
Moscow, 러시아 연방, 119992
- Pfizer Investigational Site
-
Moscow, 러시아 연방, 123182
- Pfizer Investigational Site
-
-
-
-
-
Bucharest, 루마니아, 7000
- Pfizer Investigational Site
-
Bucharest, 루마니아, 771181
- Pfizer Investigational Site
-
Bucuresti, 루마니아, 7000
- Pfizer Investigational Site
-
Bucuresti, 루마니아, 71406
- Pfizer Investigational Site
-
Cluj-Napoca, 루마니아, 3400
- Pfizer Investigational Site
-
Timisoara, 루마니아, 1900
- Pfizer Investigational Site
-
-
-
-
DF
-
Mexico City, DF, 멕시코, 03100
- Pfizer Investigational Site
-
Mexico City, DF, 멕시코, 06720
- Pfizer Investigational Site
-
Mexico City, DF, 멕시코, 14050
- Pfizer Investigational Site
-
-
Mexico DF
-
Mexico City, Mexico DF, 멕시코, 07760
- Pfizer Investigational Site
-
-
Mexico, DF
-
Mexico City, Mexico, DF, 멕시코, 14000
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Fairhope, Alabama, 미국, 36532
- Pfizer Investigational Site
-
Mobile, Alabama, 미국, 36608
- Pfizer Investigational Site
-
Mobile, Alabama, 미국, 36604
- Pfizer Investigational Site
-
Mobile, Alabama, 미국, 36607
- Pfizer Investigational Site
-
Mobile, Alabama, 미국, 36602
- Pfizer Investigational Site
-
-
Arizona
-
Tucson, Arizona, 미국, 85724
- Pfizer Investigational Site
-
-
Arkansas
-
Fayetteville, Arkansas, 미국, 72703
- Pfizer Investigational Site
-
Springdale, Arkansas, 미국, 72764
- Pfizer Investigational Site
-
-
California
-
Anaheim, California, 미국, 92801
- Pfizer Investigational Site
-
Anaheim, California, 미국, 92805
- Pfizer Investigational Site
-
Los Angeles, California, 미국, 90033
- Pfizer Investigational Site
-
Los Angeles, California, 미국, 90095-1778
- Pfizer Investigational Site
-
Orange, California, 미국, 92868
- Pfizer Investigational Site
-
Sacramento, California, 미국, 95825
- Pfizer Investigational Site
-
Sacramento, California, 미국, 95819
- Pfizer Investigational Site
-
San Francisco, California, 미국, 94115
- Pfizer Investigational Site
-
San Francisco, California, 미국, 94118-3110
- Pfizer Investigational Site
-
San Francisco, California, 미국, 94143-0648
- Pfizer Investigational Site
-
Santa Rosa, California, 미국, 95403
- Pfizer Investigational Site
-
Santa Rosa, California, 미국, 95404
- Pfizer Investigational Site
-
Stanford, California, 미국, 94305
- Pfizer Investigational Site
-
-
Colorado
-
Fort Collins, Colorado, 미국, 80524
- Pfizer Investigational Site
-
Fort Collins, Colorado, 미국, 80528
- Pfizer Investigational Site
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06520
- Pfizer Investigational Site
-
New Haven, Connecticut, 미국, 06504
- Pfizer Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, 미국, 20010
- Pfizer Investigational Site
-
-
Florida
-
Brandon, Florida, 미국, 33511
- Pfizer Investigational Site
-
Clearwater, Florida, 미국, 33756
- Pfizer Investigational Site
-
Hudson, Florida, 미국, 34667
- Pfizer Investigational Site
-
Jacksonville, Florida, 미국, 32216
- Pfizer Investigational Site
-
Melbourne, Florida, 미국, 32901
- Pfizer Investigational Site
-
Melbourne, Florida, 미국, 32901-3276
- Pfizer Investigational Site
-
Pensacola, Florida, 미국, 32504
- Pfizer Investigational Site
-
Pensacola, Florida, 미국, 32514
- Pfizer Investigational Site
-
Sarasota, Florida, 미국, 34239
- Pfizer Investigational Site
-
St. Petersburg, Florida, 미국, 33709
- Pfizer Investigational Site
-
Tampa, Florida, 미국, 33613
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Pfizer Investigational Site
-
Augusta, Georgia, 미국, 30901
- Pfizer Investigational Site
-
-
Indiana
-
Fort Wayne, Indiana, 미국, 46804
- Pfizer Investigational Site
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- Pfizer Investigational Site
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, 미국, 21215
- Pfizer Investigational Site
-
Salisbury, Maryland, 미국, 21801
- Pfizer Investigational Site
-
Takoma Park, Maryland, 미국, 20912
- Pfizer Investigational Site
-
Towson, Maryland, 미국, 21204
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- Pfizer Investigational Site
-
Cambridge, Massachusetts, 미국, 02138
- Pfizer Investigational Site
-
-
Michigan
-
Detroit, Michigan, 미국, 48202
- Pfizer Investigational Site
-
Livonia, Michigan, 미국, 48150
- Pfizer Investigational Site
-
Muskegon, Michigan, 미국, 49444
- Pfizer Investigational Site
-
Royal Oak, Michigan, 미국, 48073
- Pfizer Investigational Site
-
-
New York
-
New York, New York, 미국, 10029
- Pfizer Investigational Site
-
Rochester, New York, 미국, 14621
- Pfizer Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45219
- Pfizer Investigational Site
-
Cincinnati, Ohio, 미국, 45236
- Pfizer Investigational Site
-
Dayton, Ohio, 미국, 45408
- Pfizer Investigational Site
-
Dayton, Ohio, 미국, 45414
- Pfizer Investigational Site
-
Sandusky, Ohio, 미국, 44870
- Pfizer Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73112
- Pfizer Investigational Site
-
Tulsa, Oklahoma, 미국, 74104
- Pfizer Investigational Site
-
-
Oregon
-
Portland, Oregon, 미국, 97210
- Pfizer Investigational Site
-
-
Pennsylvania
-
Altoona, Pennsylvania, 미국, 16601
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, 미국, 15212
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, 미국, 15224
- Pfizer Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- Pfizer Investigational Site
-
Charleston, South Carolina, 미국, 29406
- Pfizer Investigational Site
-
Charleston, South Carolina, 미국, 29401
- Pfizer Investigational Site
-
Charleston, South Carolina, 미국, 29424
- Pfizer Investigational Site
-
-
Tennessee
-
Memphis, Tennessee, 미국, 38120
- Pfizer Investigational Site
-
-
Texas
-
Amarillo, Texas, 미국, 79106
- Pfizer Investigational Site
-
Fort Worth, Texas, 미국, 76107
- Pfizer Investigational Site
-
Fort Worth, Texas, 미국, 76107-2699
- Pfizer Investigational Site
-
Houston, Texas, 미국, 77030
- Pfizer Investigational Site
-
Irving, Texas, 미국, 75061
- Pfizer Investigational Site
-
-
Vermont
-
Burlington, Vermont, 미국, 05401
- Pfizer Investigational Site
-
-
Virginia
-
Annandale, Virginia, 미국, 22003
- Pfizer Investigational Site
-
Falls Church, Virginia, 미국, 22042
- Pfizer Investigational Site
-
Fredericksburg, Virginia, 미국, 22401
- Pfizer Investigational Site
-
Norfolk, Virginia, 미국, 23507
- Pfizer Investigational Site
-
-
Washington
-
Tacoma, Washington, 미국, 98405
- Pfizer Investigational Site
-
-
Wisconsin
-
Elkhorn, Wisconsin, 미국, 53121
- Pfizer Investigational Site
-
Madison, Wisconsin, 미국, 53792
- Pfizer Investigational Site
-
Milwaukee, Wisconsin, 미국, 53215
- Pfizer Investigational Site
-
-
-
-
-
Brussel, 벨기에, 1090
- Pfizer Investigational Site
-
Bruxelles, 벨기에, 1070
- Pfizer Investigational Site
-
Edegem, 벨기에, 2650
- Pfizer Investigational Site
-
Genk, 벨기에, 3600
- Pfizer Investigational Site
-
Liege, 벨기에, B-4000
- Pfizer Investigational Site
-
-
-
-
-
Orebro, 스웨덴, SE-701 85
- Pfizer Investigational Site
-
Stockholm, 스웨덴, 171 76
- Pfizer Investigational Site
-
Uppsala, 스웨덴, SE 751 85
- Pfizer Investigational Site
-
-
-
-
-
Bern, 스위스, 3010
- Pfizer Investigational Site
-
Geneve 14, 스위스, 1211
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, 스페인, 08025
- Pfizer Investigational Site
-
Barcelona, 스페인, 08907
- Pfizer Investigational Site
-
Madrid, 스페인, 28046
- Pfizer Investigational Site
-
Valencia, 스페인, 46010
- Pfizer Investigational Site
-
-
-
-
-
Bratislava, 슬로바키아, 833 48
- Pfizer Investigational Site
-
Kosice, 슬로바키아, 040-11
- Pfizer Investigational Site
-
-
-
-
-
Singapore, 싱가포르, 168752
- Pfizer Investigational Site
-
-
-
-
-
Buenos Aires, 아르헨티나, 1118
- Pfizer Investigational Site
-
Buenos Aires, 아르헨티나, 1416
- Pfizer Investigational Site
-
Buenos Aires, 아르헨티나, C1405DCS
- Pfizer Investigational Site
-
-
Pcia. de Buenos Aires
-
Morón, Pcia. de Buenos Aires, 아르헨티나, 1708
- Pfizer Investigational Site
-
-
-
-
-
Dublin, 아일랜드
- Pfizer Investigational Site
-
-
-
-
-
Edinburgh, 영국, Eh3 9YW
- Pfizer Investigational Site
-
Liverpool, 영국
- Pfizer Investigational Site
-
London, 영국, SE1 7EH
- Pfizer Investigational Site
-
London, 영국, E2 9JX
- Pfizer Investigational Site
-
Middlesbrough, 영국, TS4 3BW
- Pfizer Investigational Site
-
Oxford, 영국, OX3 9DU
- Pfizer Investigational Site
-
-
-
-
-
Graz, 오스트리아, 8036
- Pfizer Investigational Site
-
-
-
-
-
Beer Sheva, 이스라엘
- Pfizer Investigational Site
-
Haifa, 이스라엘
- Pfizer Investigational Site
-
Haifa, 이스라엘, 34362
- Pfizer Investigational Site
-
Holon, 이스라엘, 58100
- Pfizer Investigational Site
-
Jerusalem, 이스라엘, 91120
- Pfizer Investigational Site
-
Jerusalem, 이스라엘, 91031
- Pfizer Investigational Site
-
Jerusalem, 이스라엘, 91004
- Pfizer Investigational Site
-
Petach-Tikva, 이스라엘, 49261
- Pfizer Investigational Site
-
Ramat-Gan, 이스라엘
- Pfizer Investigational Site
-
Rehovot, 이스라엘
- Pfizer Investigational Site
-
Tel Aviv, 이스라엘
- Pfizer Investigational Site
-
Tel Hashomer, 이스라엘, 52651
- Pfizer Investigational Site
-
-
-
-
-
Firenze, 이탈리아, 50134
- Pfizer Investigational Site
-
Milano, 이탈리아, 20138
- Pfizer Investigational Site
-
Pavia, 이탈리아, 27100
- Pfizer Investigational Site
-
Pisa, 이탈리아, 56125
- Pfizer Investigational Site
-
-
-
-
-
Ceske Budejovice, 체코 공화국, 370 87
- Pfizer Investigational Site
-
Prague, 체코 공화국, 100 34
- Pfizer Investigational Site
-
Prague, 체코 공화국, 128 00
- Pfizer Investigational Site
-
Prague, 체코 공화국, 14220
- Pfizer Investigational Site
-
Prague, 체코 공화국, 150 00
- Pfizer Investigational Site
-
Prague 5, 체코 공화국, 15500
- Pfizer Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, 캐나다, T6G 2B7
- Pfizer Investigational Site
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V6Z 1Y6
- Pfizer Investigational Site
-
Vancouver, British Columbia, 캐나다, V5Z 1M9
- Pfizer Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, 캐나다, R3A 1R9
- Pfizer Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, 캐나다, B3H 3A7
- Pfizer Investigational Site
-
-
Ontario
-
Kingston, Ontario, 캐나다, K7L 2V7
- Pfizer Investigational Site
-
Kingston, Ontario, 캐나다, K7L 5G2
- Pfizer Investigational Site
-
London, Ontario, 캐나다, N6A 5A5
- Pfizer Investigational Site
-
Toronto, Ontario, 캐나다, M5G 2C4
- Pfizer Investigational Site
-
Toronto, Ontario, 캐나다, M4N 3M5
- Pfizer Investigational Site
-
-
Quebec
-
Fleurimont, Quebec, 캐나다, J1H 5N4
- Pfizer Investigational Site
-
Montreal, Quebec, 캐나다, H3A 1A1
- Pfizer Investigational Site
-
Montreal, Quebec, 캐나다, H1T 1C8
- Pfizer Investigational Site
-
-
Saskatchewan
-
Regina, Saskatchewan, 캐나다, S4P 0W5
- Pfizer Investigational Site
-
Saskatoon, Saskatchewan, 캐나다, S7N 0W8
- Pfizer Investigational Site
-
-
-
-
-
Bogota, 콜롬비아
- Pfizer Investigational Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, 콜롬비아, 000
- Pfizer Investigational Site
-
-
Santander
-
Floridablanca, Santander, 콜롬비아, 000
- Pfizer Investigational Site
-
-
Valle
-
Cali, Valle, 콜롬비아, Nap
- Pfizer Investigational Site
-
-
-
-
-
Bialystok, 폴란드, 15-276
- Pfizer Investigational Site
-
Krakow, 폴란드, 31-202
- Pfizer Investigational Site
-
Poznan, 폴란드, 61-848
- Pfizer Investigational Site
-
Szczecin, 폴란드, 70-111
- Pfizer Investigational Site
-
Warszawa, 폴란드, 02-097
- Pfizer Investigational Site
-
-
-
-
-
Kuopio, 핀란드
- Pfizer Investigational Site
-
Kuopio, 핀란드, 70211
- Pfizer Investigational Site
-
Oulu, 핀란드
- Pfizer Investigational Site
-
Turku, 핀란드, FIN-20520
- Pfizer Investigational Site
-
-
-
-
Queensland
-
Auchenflower, Queensland, 호주, 4066
- Pfizer Investigational Site
-
-
South Australia
-
Ashford, South Australia, 호주, 5035
- Pfizer Investigational Site
-
-
Victoria
-
Clayton, Victoria, 호주, 3168
- Pfizer Investigational Site
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion criteria:
- Patients expected to receive in-hospital pain medication for pain after coronary artery bypass graft surgery for at least 3 full days and pain medication over a 10-day period
- New York Heart Association Class I to III or cardiac ejection fraction of at least 35% before surgery
- Body mass index of less than or equal to 40 kg/m2 and weight of >55 kg
- Patients scheduled to undergo an isolated (bypass grafting only without valve replacement, significant aortic reconstruction, or ventriculoplasty) primary CABG surgery via median sternotomy, using cardiopulmonary bypass
Exclusion criteria:
- Patient has undergone or is going to have emergency coronary artery bypass graft surgery or surgery without cardiopulmonary bypass procedure
- Symptomatic peripheral vascular disease
- Heart attack within 48 hours of surgery
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 비
|
Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications.
A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1.
On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals.
After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
|
|
실험적: 씨
|
Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications.
A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1.
On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals.
After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
|
|
위약 비교기: ㅏ
|
Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications.
A second dose of parecoxib sodium 20 mg IV was administered on Day 1.
On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals.
After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Combined incidence of the number of patients with at least 1 confirmed clinically relevant adverse event (CRAE)
기간: Day 30
|
Day 30
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
부작용
기간: 30일
|
30일
|
|
활력징후
기간: 30일
|
30일
|
|
Combined incidence of the number of patients with at least 1 reported CRAE and the combined incidence of the number of patients with specific reported CRAEs summarized according to the categories listed above
기간: Day 30
|
Day 30
|
|
Rate of supplemental analgesia consumed
기간: Days 1-10
|
Days 1-10
|
|
Summed Pain Intensity (SPI) of sternotomy alone and overall body pain over 8 hours (SPI 8)
기간: Day 1
|
Day 1
|
|
Opioid-related Symptoms Distress Scale (OR-SDS)
기간: Days 1-10
|
Days 1-10
|
|
Time to last Patient Controlled Analgesia (PCA) dose
|
|
|
Recovery measures (length of stay, intensive care unit/hospital recovery and eligibility for discharge)
|
|
|
Combined incidence of the number of patients with specific confirmed CRAEs in categories of cardiovascular thromboembolic CRAEs, renal CRAEs, upper gastrointestinal ulcer CRAEs, and wound healing complication CRAEs
기간: Day 30
|
Day 30
|
|
Serious adverse events
기간: Day 30
|
Day 30
|
|
Clinical laboratory assessments
기간: Day 30
|
Day 30
|
|
Peak Pain Intensity (PPI) of sternotomy alone and overall body pain
기간: Days 1-10
|
Days 1-10
|
|
Patient's and Physician's Global Evaluation of Study Medication
기간: At time of transition from intravenous to oral medication and final visit/early termination
|
At time of transition from intravenous to oral medication and final visit/early termination
|
|
Modified Brief Pain Inventory-short form (mBPI-sf)
기간: Days 1-10
|
Days 1-10
|
|
SPI of sternotomy alone and overall body pain over 12 hours (SPI 12) and 24 hours (SPI 24)
기간: Days 1-10
|
Days 1-10
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2003년 1월 1일
연구 완료 (실제)
2004년 1월 1일
연구 등록 날짜
최초 제출
2008년 3월 7일
QC 기준을 충족하는 최초 제출
2008년 3월 7일
처음 게시됨 (추정)
2008년 3월 14일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2008년 10월 10일
QC 기준을 충족하는 마지막 업데이트 제출
2008년 10월 9일
마지막으로 확인됨
2008년 3월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- PARA-0505-071
- A3481015
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .